Rogel Cancer Center: University of Michigan

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1991-01-01

Employees: -

Market Cap: -

Website: http://www.rogelcancercenter.org

Clinical Trials

Solution-Focused Brief Therapy for Support of Psychological Distress in Adolescent and Young Adult Cancer Survivors

Not Applicable

Not yet recruiting

Conditions: Hematopoietic and Lymphatic System Neoplasm
Malignant Solid Neoplasm

First Posted Date: 2025-04-23

Last Posted Date: 2025-04-23

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 60

Registration Number: NCT06941324

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Navigation Interventions to Improve Cascade Genetic Testing Among Relatives of Patients With Hereditary Cancer Syndromes

Not Applicable

Not yet recruiting

Conditions: Hereditary Malignant Neoplasm
Hereditary Neoplastic Syndrome

First Posted Date: 2025-04-15

Last Posted Date: 2025-05-13

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 500

Registration Number: NCT06927947

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

CIPN Decision Aid for the Improvement of Chemotherapy Decision Making in Patients With Breast Cancer

Not Applicable

Recruiting

Conditions: Breast Carcinoma

First Posted Date: 2025-04-08

Last Posted Date: 2025-04-08

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 20

Registration Number: NCT06915168

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors

Phase 1

Not yet recruiting

Conditions: Recurrent Diffuse Hemispheric Glioma, H3 G34-Mutant
Recurrent Malignant Brain Neoplasm
Resectable Brain Neoplasm

Interventions: Genetic: Ad-hCMV-Flt3L
Genetic: Ad-hCMV-TK
Procedure: Biospecimen Collection
Procedure: Magnetic Resonance Imaging
Other: Survey Administration
Procedure: Tumor Resection
Drug: Valacyclovir

First Posted Date: 2025-04-06

Last Posted Date: 2025-04-06

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 11

Registration Number: NCT06914479

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial

Phase 1

Not yet recruiting

Conditions: Locally Advanced Clear Cell Renal Cell Carcinoma
Locally Advanced Sarcomatoid Renal Cell Carcinoma
Metastatic Sarcomatoid Renal Cell Carcinoma
Metastatic Clear Cell Renal Cell Carcinoma
Stage III Renal Cell Cancer AJCC v8
Stage IV Renal Cell Cancer AJCC v8

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Biological: Ipilimumab
Dietary Supplement: Inulin
Procedure: Magnetic Resonance Imaging
Biological: Nivolumab
Other: Questionnaire Administration

First Posted Date: 2025-03-10

Last Posted Date: 2025-05-02

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 55

Registration Number: NCT06866262

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation

Phase 2

Not yet recruiting

Conditions: Allogeneic Stem Cell Transplant

Interventions: Drug: Iron chelation
Drug: Potato Resistant Starch

First Posted Date: 2025-01-20

Last Posted Date: 2025-05-11

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 50

Registration Number: NCT06784336

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

Trial of Exercise Therapy in Familial Adenomatous Polyp (FAP)

Not Applicable

Not yet recruiting

Conditions: Familial Adenomatous Polyposis

First Posted Date: 2024-10-15

Last Posted Date: 2025-04-18

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 32

Registration Number: NCT06641310

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Phase 1

Recruiting

Conditions: Castration-Resistant Prostate Carcinoma
Metastatic Prostate Adenocarcinoma
Stage IVB Prostate Cancer AJCC v8

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Bone Scan
Procedure: Computed Tomography
Drug: Enzalutamide
Drug: Ruxolitinib

First Posted Date: 2024-09-27

Last Posted Date: 2025-04-08

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 39

Registration Number: NCT06616155

Locations: 🇺🇸
Rush University, Chicago, Illinois, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States

Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial

Phase 2

Recruiting

Conditions: Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
Breast Ductal Carcinoma In Situ
Localized Breast Carcinoma

Interventions: Procedure: Biospecimen Collection
Drug: Fezolinetant
Drug: Placebo Administration
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2024-09-27

Last Posted Date: 2025-05-08

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 36

Registration Number: NCT06617455

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma

Phase 2

Recruiting

Conditions: Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck
Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck
Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8

Interventions: Procedure: Computed Tomography
Other: Digital Photography
Procedure: Magnetic Resonance Imaging
Biological: Pembrolizumab

First Posted Date: 2024-08-30

Last Posted Date: 2025-03-11

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 22

Registration Number: NCT06580054

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Home Terms & Conditions Privacy Policy